reports
IFF Chief Financial and Business Transformation Officer Glenn Richter ...
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) today announced that Glenn Richter, IFF’s Chief Financial and Business Transformation Officer, plans to retire Dec. 31, 2024 after a three-year tenure with the company. A succession process has been initiated to evaluate internal and external candidates to succeed Richter as CFO. “During his time at IFF, Glenn has driven multiple actions to improve our balance sheet and position the company for financial success,” said Erik Fyrwald, IFF CEO. “We have benefited from his experience and commitment to transformation. Notably, the work he has led on por...
Apple Hospitality REIT Reports Results of Operations for First Quarter...
RICHMOND, Va.--(BUSINESS WIRE)-- Apple Hospitality REIT, Inc. (NYSE: APLE) (the “Company” or “Apple Hospitality”) today announced results of operations for the first quarter ended March 31, 2024. Apple Hospitality REIT, Inc. Selected Statistical and Financial Data As of and For the Three Months Ended March 31 (Unaudited) (in thousands, except statistical and per share amounts)(1) Three Months Ended March 31, 2024 2023 % Change ...
IFF Reports First Quarter 2024 Results
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Consolidated Summary: Reported (GAAP) Adjusted (Non-GAAP)1 Sales Income Before Taxes EPS Operating EBITDA Operating EBITDA Margin EPS ex Amortization $2.9 B $115 M $0.23 $578 M 19.9% $1.13 Management Commentary "We have started the year well, with good results across the majority ...
Corvus Pharmaceuticals Provides Business Update and Reports First Quar...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefined Deep Response Threshold Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharm...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 06-May-2024 / 14:32 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tr...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 03-May-2024 / 14:31 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tr...
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2...
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register f...
Fidus Investment Corporation Announces First Quarter 2024 Financial Re...
Fidus Investment Corporation Announces First Quarter 2024 Financial Results Board of Directors Declared Total Dividends of $0.59 per Share for Second Quarter 2024Base Dividend of $0.43 and Supplemental Dividend of $0.16 Per Share EVANSTON, Ill., May 02, 2024 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” or the “Company”), a provider of customized debt and equity financing solutions, primarily to lower middle-market companies based in the United States, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial...
Corvus Pharmaceuticals to Provide Business Update and First Quarter 20...
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domesti...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 02-May-2024 / 14:39 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tr...
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered D...
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share (the “Common Stock”) and pre-funded warrants to purchase Common Stock in...
SLB OneSubsea and Subsea7 Sign Long-Term Strategic Collaboration Agree...
HOUSTON--(BUSINESS WIRE)-- SLB (NYSE: SLB) has announced the signing of a new long-term strategic collaboration agreement between Equinor ASA and the Subsea Integration Alliance (which comprises OneSubsea™ and Subsea7). The agreement paves the way for exploratory work to begin on two projects: the Wisting field offshore Norway and Bay Du Nord, off Newfoundland and Labrador, Canada. This press release features multimedia. View the full release here: The strategic collaboration agreement enables early information sharing, technology innovation and other collaborative benefits critical to unlock...
North American Construction Group Ltd. Announces Results for the First...
North American Construction Group Ltd. Announces Results for the First Quarter Ended March 31, 2024 ACHESON, Alberta, May 01, 2024 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG”) (TSX:NOA/NYSE:NOA) today announced results for the first quarter ended March 31, 2024. Unless otherwise indicated, financial figures are expressed in Canadian dollars, and comparisons are to the prior period ended March 31, 2023. First Quarter 2024 Highlights: Combined revenue of $345.7 million compared favorably to $322.3 million in the same period last year, is a first quarter record a...
IFF Declares Dividend for Second Quarter 2024
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2024 to shareholders of record as of June 21, 2024. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners ...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 01-May-2024 / 14:53 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tr...
- Jesse Redmond
Outperforming in Nevada; Expanding Nationally
CLS Holdings is a vertically integrated cannabis company with core operations in Nevada. Nevada is the 32nd most populous state with 3.14 million residents. The state had 40.8 million visitors in 2023, ranking it fifth worldwide in tourism. Nevada ranks second in cannabis sales per capita, driven by the large number of tourists. The company owns and operates Oasis Cannabis Dispensary, a popular retail cannabis store for locals and visitors. It is a ~2,500-square-foot recreational and medical dis...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-2...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 30-Apr-2024 / 14:20 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tr...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 29-Apr-2024 / 13:44 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tr...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corp
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corp 26-Apr-2024 / 14:51 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.